and advanced materials industries, with the result that the methodology known as ''combinatorial chemistry'' is now relatively ubiquitous in companies conducting research in advanced materials, catalysts, and polymers.Many of the methodologies adopted by advanced materials researchers were developed for drug discovery in the pharmaceuticals industry. Drug discovery had entered the new paradigm of combinatorial chemistry and high throughput screening (HTS) in the 1980s, led independently by Furka (5) and Geysen & co-workers (6). The major industry driver was to develop new therapeutics with very tight time-and cost constraints. Traditional techniques of synthesizing and characterizing synthetic targets one-by-one were too slow. Combinatorial chemists indicated that, in theory, the number of potential drug targets-small organic molecules containing C, H, N, and O atoms -approaches 10 50 , although the number of compounds considered useful is probably closer to 10 10 -10 15 (7), and that the only way to screen this diversity was by using massively parallel synthesis and characterization techniques. A number of review articles have covered these pioneers and subsequent developments (8). The commercial importance, and acceptance, of combinatorial methods became obvious when, in 1994 and 1995, Eli Lilly acquired Sphinx for $80 million, Glaxo plc (now GlaxoSmithKline, GSK) acquired technology leader Affymax for $533 million, and Marion Merrell Dow bought Selectide for $58 million (9). Experimental throughputs using 96-well titre plates were on the order hundreds to thousands of reactions per day (a ''hit'' in the discovery phase). By 1999, the ability to robotically synthesize and characterize 1 million distinct organic compounds per year was realized by some pharmaceutical companies, driving down R&D costs per sample by two orders of magnitude, to $1 or less per ''hit''.Today, many chemical and advanced materials companies have implemented some form of HTE in their discovery research phases, through internal investment, mergers, and acquisitions. The market drivers-global pressures for higher performance specialty materials and higher profits on commodity materials-have pressed these industries to increase productivity in their new product discovery and process development phases. HTE for materials often has little similarity with methods developed in the drug discovery arena, however, researchers have quite effectively leveraged many methods and tools from the pharmaceutical applications (10). This is evident in the area of industrial catalysis, where HTE utilized in the discovery and process development phases have cut concept-to-launch cycle times in half; this represents significant cost savings as well as commercial advantages such as market penetration and intellectual property position.
The New Paradigm for Materials Research2.1. Application Areas. Many of the market factors that influenced drug discovery are presently driving a need for reducing the cycle time for the discovery and process development of new ad...